Evome Medical Technologies Inc. EVMT.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -17.11% | 18.95% | 50.31% | 52.98% | 61.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.11% | 18.95% | 50.31% | 52.98% | 61.47% |
| Cost of Revenue | -16.10% | 15.55% | 46.07% | 43.84% | 58.01% |
| Gross Profit | -19.02% | 25.94% | 58.88% | 72.48% | 68.44% |
| SG&A Expenses | -21.15% | 14.95% | 67.48% | 71.18% | 106.37% |
| Depreciation & Amortization | -5.72% | 26.47% | 74.56% | 113.88% | 155.98% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.21% | 16.01% | 54.66% | 55.82% | 76.81% |
| Operating Income | 18.05% | 6.16% | -106.84% | -97.24% | -908.43% |
| Income Before Tax | -182.89% | 10.25% | 23.72% | 34.17% | 49.94% |
| Income Tax Expenses | 100.59% | 100.86% | 100.58% | 101.53% | -1,603.24% |
| Earnings from Continuing Operations | -389.35% | -7.60% | 10.02% | 21.39% | 70.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -389.35% | -7.60% | 10.02% | 21.39% | 70.67% |
| EBIT | 18.05% | 6.16% | -106.84% | -97.24% | -908.43% |
| EBITDA | 18.34% | 23.87% | -150.38% | -109.14% | -923.46% |
| EPS Basic | -226.32% | 24.82% | 36.78% | 42.93% | 71.63% |
| Normalized Basic EPS | 81.98% | 84.54% | 77.74% | 77.89% | -2,233.33% |
| EPS Diluted | -226.32% | 25.69% | 37.68% | 43.74% | 75.94% |
| Normalized Diluted EPS | 81.98% | 84.54% | 77.74% | 77.89% | -2,233.33% |
| Average Basic Shares Outstanding | 29.30% | 36.24% | 34.64% | 31.41% | 32.19% |
| Average Diluted Shares Outstanding | 29.30% | 36.24% | 34.64% | 31.41% | 32.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |